Do you have poorly controlled Atopic Dermatitis (eczema)?

If so, you may be eligible to take part in a National Institutes of Health-sponsored research study to examine the effect of a new treatment called dupilumab on your skin disease.

You may be eligible if:

- You are a male or female between the ages of 18 and 65 years old
- You have moderate to severe atopic dermatitis and have at least three active areas of disease on your arms or legs
- You have not previously received the FDA-approved drug, dupilumab, (also called Dupixent) for the treatment of your atopic dermatitis or any other allergic disease

What’s involved?

- About 10 visits to the clinic over a 6 month time period, plus phone calls
- Blood and skin sample collection, including skin biopsy
- Subcutaneous (just under the skin) injections of dupilumab or placebo

If you decide to participate you will receive:

- Ten or 16 weeks of treatment with dupilumab (Dupixent) at no cost to you or your insurance provider
- Study related medical exams
- Blood test results
- Financial compensation

For more information, please call the University of Florida Department of Dermatology ADRN Study Coordinator at 352 594 1547

Principal Investigator: Dr. Anna De Benedetto

ADFDRN
Atopic Dermatitis Research Network

Department of Dermatology
UNIVERSITY OF FLORIDA